Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

EPX-100 (Clemizole Hydrochloride) som tilleggsterapi hos barn med Lennox Gastaut syndrom

8. oktober 2026 oppdatert av: Epygenix

En 20-ukers multisenter, randomisert, dobbeltblind, placebokontrollert, begrepstesting av EPX-100 (Clemizole Hydrochloride) som tilleggsterapi hos barn med Lennox-Gastaut syndrom

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCl as adjunctive therapy in children and adult participants with LGS.

The study will consist of an Observational Period, a Double-Blind (DB) Period, and an optional Open-Label Extension (OLE) Period.

Studietype

Intervensjonell

Registrering (Antatt)

260

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72202
        • Aktiv, ikke rekrutterende
        • Arkansas Children's Hospital
    • California
      • Orange, California, Forente stater, 92868
        • Aktiv, ikke rekrutterende
        • UC Irvine Medical Center
    • Florida
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami Miller School of Medicine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kamil Detyniecki, MD
      • Orlando, Florida, Forente stater, 32804
        • Rekruttering
        • AdventHealth Innovation Tower
        • Hovedetterforsker:
          • Holly Skinner, DO
      • Orlando, Florida, Forente stater, 34746
        • Suspendert
        • Rare Disease Research
      • Winter Park, Florida, Forente stater, 32789
        • Aktiv, ikke rekrutterende
        • Pediatric Neurology and Epilepsy Specialists
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Re:Cognition Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Antonio Iglesias, MD
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • Norton Children's Medical Center
        • Hovedetterforsker:
          • Jaime Shoup, MD
        • Ta kontakt med:
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Aktiv, ikke rekrutterende
        • Henry Ford Hospital
    • Minnesota
      • Roseville, Minnesota, Forente stater, 55102
        • Rekruttering
        • Minnesota Epilepsy Group, P.A.
        • Ta kontakt med:
        • Hovedetterforsker:
          • Stephanie Ahrens, MD
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68114
        • Rekruttering
        • Children's Nebraska
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sookyong Koh
    • New Jersey
      • Marlboro, New Jersey, Forente stater, 07746
        • Rekruttering
        • Tekton Research
        • Hovedetterforsker:
          • Amor Mehta, MD
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Weill Cornell Medicine/New York Presbyterian Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Asim Shahid, MD
      • New York, New York, Forente stater, 10016-4852
        • Rekruttering
        • NYU Comprehensive Epilepsy Center - BRANY - PPDS
        • Hovedetterforsker:
          • Dana Price
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28211
        • Rekruttering
        • On-Site Clinical Solution
        • Hovedetterforsker:
          • Robert Nahouraii
        • Ta kontakt med:
      • Charlotte, North Carolina, Forente stater, 28207
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Muhammad Zafar, MD
      • Morrisville, North Carolina, Forente stater, 27560
        • Rekruttering
        • PPD Virtual-Science 37, Inc.
        • Hovedetterforsker:
          • Antonio Iglesias, MD
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Hovedetterforsker:
          • Eric Marsh, MD
    • Texas
      • Dallas, Texas, Forente stater, 75235
        • Rekruttering
        • Children's Health Specialty Center
        • Hovedetterforsker:
          • Charuta Joshi
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • UTHealth Houston
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mary Koenig, MD
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • Clinical Neurosciences Center
        • Hovedetterforsker:
          • Angela Peters, MD
    • Andhra Pradesh
      • Hyderabad, Andhra Pradesh, India, 500082
        • Rekruttering
        • Nizams Institute of Medical Sciences
        • Hovedetterforsker:
          • Surya Prabha Turaga
      • Hyderabad, Andhra Pradesh, India, 500081
        • Rekruttering
        • Yashoda Hospitals Hitec City
        • Hovedetterforsker:
          • Lokesh Lingappa
    • Gujarat
      • Ahmedabad, Gujarat, India, 380054
        • Rekruttering
        • Royal Institute of Child Neurosciences
        • Hovedetterforsker:
          • Nitish Vora
      • Surat, Gujarat, India, 395002
        • Rekruttering
        • Saachi Children Hospital
        • Hovedetterforsker:
          • Ritesh Shah
    • Kerala
      • Calicut, Kerala, India, 673016
        • Rekruttering
        • Aster Malabar Institute of Medical Sciences Ltd
        • Hovedetterforsker:
          • Smilu Mohanlal
      • Catanzaro, Italia, 88100
        • Rekruttering
        • Azienda Ospedaliera Universitaria Renato Dulbecco - AO Mater Domini
        • Hovedetterforsker:
          • Antonio Gambardella
      • Florence, Italia, 50139
        • Rekruttering
        • Azienda Ospedaliero Universitaria A Meyer
        • Hovedetterforsker:
          • Renzo Guerrini
      • Milan, Italia, 20133
        • Rekruttering
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
        • Hovedetterforsker:
          • Giuseppe Didato
      • Pavia, Italia, 27100
        • Rekruttering
        • Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS
        • Hovedetterforsker:
          • Elena Tartara
    • Liguria
      • Genoa, Liguria, Italia, 16147
        • Rekruttering
        • IRCCS Istituto Giannina Gaslini
        • Hovedetterforsker:
          • Maria Margherita Mancardi
      • Genoa, Liguria, Italia, 16132
        • Rekruttering
        • IRCCS Azienda Ospedaliera Metropolitan
        • Hovedetterforsker:
          • Flavio Villani
    • Molise
      • Pozzilli, Molise, Italia, 86077
        • Rekruttering
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
        • Hovedetterforsker:
          • Alfredo D'Aniello
      • Beijing, Kina, 100045
        • Rekruttering
        • Beijing Children's Hospital, Capital Medical University - PIN
        • Hovedetterforsker:
          • Hui Xiong
      • Beijing, Kina, 100034
        • Rekruttering
        • Peking University First Hospital - Changqiao Campus
        • Hovedetterforsker:
          • Yuwu Jiang
      • Beijing, Kina, 100034
        • Rekruttering
        • Peking University First Hospital - Daxing Campus
        • Hovedetterforsker:
          • Yuwu Jiang
      • Changchun, Kina, 130021
        • Rekruttering
        • The First Hospital of Jilin University
        • Hovedetterforsker:
          • Jianmin Liang
      • Changsha, Kina, 410007
        • Rekruttering
        • Hunan Children's Hospital
        • Hovedetterforsker:
          • Sai Yang
      • Chengdu, Kina, 610041
        • Rekruttering
        • West China Second University Hospital, Sichuan University - Huaxi Campus
        • Hovedetterforsker:
          • Rong Luo
      • Chengdu, Kina, 610073
        • Rekruttering
        • Chengdu Women's and Children's Central Hospital
        • Hovedetterforsker:
          • Li Yan
      • Chongqing, Kina, 400014
        • Rekruttering
        • Children's Hospital of Chongqing Medical University
        • Hovedetterforsker:
          • Li Jiang
      • Guangzhou, Kina, 510260
        • Rekruttering
        • The Second Affiliated Hospital of Guangzhou Medical University
        • Hovedetterforsker:
          • Xiaorong Liu
      • Guiyang, Kina, 550004
        • Rekruttering
        • The Affiliated Hospital of Guizhou Medical University
        • Hovedetterforsker:
          • Rong Ai
      • Jinan, Kina, 250012
        • Rekruttering
        • Qilu Hospital of Shandong University
        • Hovedetterforsker:
          • Baomin Li
      • Nanchang, Kina, 330006
        • Rekruttering
        • Jiangxi Provincial Children's Hospital
        • Hovedetterforsker:
          • Yong Chen
      • Shenzhen, Kina, 518000
        • Rekruttering
        • Shenzhen Children's Hospital
        • Hovedetterforsker:
          • Dezhi Cao
      • Wuhan, Kina, 430015
        • Rekruttering
        • Wuhan Children's Hospital
        • Hovedetterforsker:
          • Dan Sun
      • Xi'an, Kina, 710004
        • Rekruttering
        • The Second Affiliated Hospital of Xi'an Jiaotong University
        • Hovedetterforsker:
          • Lin Yang
      • Xuzhou, Kina, 221006
        • Rekruttering
        • Xuzhou Children's Hospital
        • Hovedetterforsker:
          • Xiaoming Liu
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Rekruttering
        • Xiangya Hospital Central South University
        • Hovedetterforsker:
          • Jing Peng
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200062
        • Rekruttering
        • Children's Hospital of Shanghai
        • Hovedetterforsker:
          • Simei Wang
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 30-363
        • Rekruttering
        • Centrum Medyczne Plejady Magdalena Celinska
        • Hovedetterforsker:
          • Marta Zolnowska, MD
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 50-414
        • Rekruttering
        • Premium Clinic Wrocław Centrum Medyczne
        • Hovedetterforsker:
          • Monika Sluzewska-Niedzwiedz
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-829
        • Rekruttering
        • Neurosphera
        • Hovedetterforsker:
          • Beata Zwolinska
      • Bucharest, Romania, 050098
        • Rekruttering
        • Emergency University Hospital
        • Hovedetterforsker:
          • Ioana Raluca Mindruta
      • Bucharest, Romania, 041408
        • Rekruttering
        • Centrul National Clinic De Recuperare Neuropsihomotorie Copii Robanescu-Padure
        • Hovedetterforsker:
          • Madalina Leanca
      • Iași, Romania, 700309
        • Rekruttering
        • Sf. Maria Children Emergency Clinical Hospital Iasi
        • Hovedetterforsker:
          • Ioana Grigore
      • Belgrade, Serbia, 11000
        • Rekruttering
        • Mother and Child Health Care Institute of Serbia Dr Vukan Cupic
        • Hovedetterforsker:
          • Biljana Vucetic Tadic
      • Belgrade, Serbia, 11000
        • Rekruttering
        • Childrens University Hospital
        • Hovedetterforsker:
          • Dimitrije Nikolic
      • Niš, Serbia, 18 000
        • Rekruttering
        • University Clinical Center Nis
        • Hovedetterforsker:
          • Tatjana Tosic
      • Novi Sad, Serbia, 21000
        • Rekruttering
        • Children and Youth Health Care Institute of Vojvodina
        • Hovedetterforsker:
          • Tatjana Redzek Mudrinic
      • Barcelona, Spania, 08025
        • Rekruttering
        • Hospital de La Santa Creu i Sant Pau
        • Hovedetterforsker:
          • Alba Sierra-Marcos
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Universitario Vall d'Hebron - PPDS
        • Hovedetterforsker:
          • Manuel Toledo Argany
      • Madrid, Spania, 28009
        • Rekruttering
        • Hospital Infantil Universitario Niño Jesus - PIN
        • Hovedetterforsker:
          • Victor Soto Insuga
      • Málaga, Spania, 29010
        • Rekruttering
        • Hospital Regional Universitario de Malaga - Hospital General
        • Hovedetterforsker:
          • Pedro Serrano
      • Pamplona, Spania, 31008
        • Rekruttering
        • Hospital Universitario de Navarra
        • Hovedetterforsker:
          • Sergio Aguilera Albesa
      • Seville, Spania, 41013
        • Rekruttering
        • Centro de Neurologia Avanzada
        • Hovedetterforsker:
          • Juan Jesús Rodríguez Uranga, MD
      • Ortahisar, Tyrkia (Türkiye), 61080
        • Rekruttering
        • Karadeniz Teknik Universitesi Farabi Hastanesi
        • Hovedetterforsker:
          • Ali Cansu
    • Eskişehir
      • Odunpazari, Eskişehir, Tyrkia (Türkiye), 26040
        • Rekruttering
        • Eskisehir Osmangazi Universitesi Saglik Uygulama ve Arastirma Hastanesi
        • Hovedetterforsker:
          • Kursat Carman
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungarn, 4032
        • Rekruttering
        • Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
        • Hovedetterforsker:
          • Monika Bessenyei

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 55 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Males or females, ages ≥2 to ≤55 years, at the time of Screening.

  2. Participant/parent/legal authorized representative (LAR) willing and able to give written informed consent/assent.

  3. Diagnosis of LGS, including:

    • Evidence of at least one type of countable major motor seizure.
    • History of electroencephalogram (EEG) consistent with LGS (abnormal background activity, and one of the following: 1) slow spike-wave discharges [<2.5 Hz], or 2) paroxysmal fast activity during sleep).
    • Abnormal cognitive development.
    • Onset of seizures at 11 years of age or younger.

Key Exclusion Criteria:

  1. Known sensitivity, allergy, or previous exposure to clemizole HCl.
  2. Known history of long QT syndrome or any significant history of a serious abnormality of the electrocardiogram (ECG) (e.g., recent myocardial infarction, clinically significant arrhythmia).
  3. Family history of sudden cardiac death, unexplained death, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member.
  4. Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or progressive central nervous system disease, metabolic illness, recent anoxic episode within the last 6 months requiring resuscitation, or progressive degenerative disease or any other condition, which in the opinion of the investigator, could affect seizure control.
  5. Epilepsy surgery planned during the study or epilepsy surgery within 6 months prior to Screening.
  6. Concomitant use of fenfluramine.
  7. Prior or concomitant use of lorcaserin.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Participants will receive their first dose of study drug following randomization.

Placebo will be administered as an oral solution.

Eksperimentell: Double-blind clemizole HCl

Participants will receive their first dose of study drug following randomization.

Clemizole HCl will be administered as an oral solution.

Andre navn:
  • EPX-100
Eksperimentell: Open-label clemizole HCl

Eligible participants who complete the DB Period will have the option to continue in the OLE Period, during which they will receive clemizole HCl for up to 3 years.

Clemizole HCl will be administered as an oral solution.

Andre navn:
  • EPX-100

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percent Change in CMMS-28
Tidsramme: From Baseline Period up to 16 weeks

Percent change in CMMS-28 from the Baseline Period through the end of the DB Period

From Baseline Period up to 16 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of Participants with ≥50% Reduction in CMMS-28
Tidsramme: From Baseline Period up to 16 weeks

Proportion of participants with ≥50% reduction in CMMS-28 from the Baseline Period through the end of the DB Period

From Baseline Period up to 16 weeks
Percent Change in CMMS-28 Seizure-free Days
Tidsramme: From Baseline Period up to 16 weeks

Percent change in CMMS-28 seizure-free days from the Baseline Period through the end of the DB Period

From Baseline Period up to 16 weeks
Clinical Global Impression of Change (CGI-C) Score
Tidsramme: Week 16

CGI-C score at the end of the DB Period

Week 16
Caregiver Global Impression of Change (CaGI-C) Score
Tidsramme: Week 16

CaGI-C score at the end of the DB Period

Week 16
Caregiver Global Impression of Change in Seizure Intensity/Duration (CaGI-CSID) Score
Tidsramme: Week 16

CaGI-CSID score at the end of the DB Period

Week 16
Change in Quality of Life Inventory (QI)-Disability Score
Tidsramme: From Baseline Period up to 16 weeks

Change in QI-disability score from Baseline to the end of the DB Period

From Baseline Period up to 16 weeks
Percent Change per 28 Days in the Number of Seizure Free Days
Tidsramme: From Baseline Period up to 16 weeks

Percent change per 28 days in the number of seizure-free days (based on all seizure types) from the Baseline Period through the end of the DB Period

From Baseline Period up to 16 weeks
Percent Change in CMMS-28
Tidsramme: From Baseline Period up to 12 weeks

Percent change in CMMS-28 from the Baseline Period through the end of the DB Maintenance Phase only

From Baseline Period up to 12 weeks
Proportion of Participants with ≥50% Reduction in CMMS-28
Tidsramme: From Baseline Period up to 12 weeks

Proportion of participants with ≥50% reduction in CMMS-28 from the Baseline Period through the end of the DB Maintenance Phase only

From Baseline Period up to 12 weeks
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: From the first dose administration of study drug up to end of the study, approximately up to 172 weeks

Incidence of TEAEs will be compared among the treatment groups

From the first dose administration of study drug up to end of the study, approximately up to 172 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Amit Ray, MD, Harmony Biosciences Management, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. april 2025

Primær fullføring (Antatt)

1. november 2026

Studiet fullført (Antatt)

1. november 2029

Datoer for studieregistrering

Først innsendt

23. september 2021

Først innsendt som oppfylte QC-kriteriene

23. september 2021

Først lagt ut (Faktiske)

4. oktober 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere